The selective expression of CaMKK2 in the myeloid subsets makes this protein an attractive immunotherapeutic target whose inhibition is expected to remodel the tumor microenvironment and stimulate anti-tumor immune responses. This evidence concerns the gene CAMKK2 and neoplasm.